EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
B.
Pérez Valderrama
Publicaciones en las que colabora con B. Pérez Valderrama (7)
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
2018
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2017
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7
-
HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
OncoTargets and Therapy, Vol. 10, pp. 4635-4643
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
2014
-
Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish expanded access program
Expert Opinion on Drug Safety, Vol. 13, Núm. 9, pp. 1165-1173